OBSN — Obseva SA Share Price
0.000.00%
Last trade - 00:00- CH₣0.14m
- -CH₣2.20m
- $19.64m
- 13
- 100
- 4
- 30
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.05 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.01 | ||
| EV to EBITDA | -0.42 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 127.16% | ||
| Return on Equity | 1576.52% | ||
| Operating Margin | 37.25% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.01 | 0.02 | 0.02 | 22.2 | 19.64 | n/a | n/a | 314.75% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: Linzagolix (OBE2109), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis and uterine fibroids; Nolasiban (OBE001), an oral oxytocin receptor antagonist, with the potential to inhibit uterine contractions at the time of embryo transfer, thereby enhancing embryo implantation during assisted reproductive technologies (ART), and OBE022, an oral and selective prostaglandin F2 alpha (PGF2a) receptor antagonist designed to control preterm labor.
Directors
- Frank Verwiel NEC (59)
- Brian O'Callaghan CEO (51)
- David Renas CFO (56)
- Fabien De Ladonchamps CAD (42)
- Jean-Pierre Gotteland CSO (56)
- Clive Bertram OTH
- Elizabeth Garner OTH (53)
- Luigi Marro OTH
- Ernest Loumaye DRC (68)
- Annette Clancy IND (67)
- Barbara Duncan IND (56)
- Edward Mathers IND (61)
- Jacky Vonderscher IND (66)
- Last Annual
- December 31st, 2022
- Last Interim
- June 30th, 2023
- Incorporated
- November 14th, 2012
- Public Since
- July 13th, 2018
- No. of Shareholders
- 21
- No. of Employees
- 15
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- SIX Swiss Exchange
- Shares in Issue
- 117,177,287
- Address
- Chemin des Aulx 12, PLAN-LES-OUATES, 1228
- Web
- https://www.obseva.com/
- Phone
- +41 225521558
- Auditors
- PricewaterhouseCoopers SA
Upcoming Events for OBSN
Obseva SA Annual Shareholders Meeting
Half Year 2024 Obseva SA Earnings Release
Similar to OBSN
Addex Therapeutics
SIX Swiss Exchange
BACHEM HOLDING AG
SIX Swiss Exchange
Basilea Pharmaceutica AG Allschwil
SIX Swiss Exchange
BB Biotech AG
SIX Swiss Exchange
Evolva Holding
SIX Swiss Exchange
FAQ
What is the Obseva SA share price?
As of Today at 19:16 UTC, shares in Obseva SA are trading at CH₣0.00. This share price information is delayed by 15 minutes.
How has the Obseva SA share price performed this year?
Shares in Obseva SA last closed at CH₣0.00 and the price had moved by -98.66% over the past 365 days. In terms of relative price strength the Obseva SA share price has underperformed the FTSE Global All Cap Index by -98.77% over the past year.
What are the analyst and broker recommendations for Obseva SA?
There is no consensus recommendation for this security.
Find out moreWhat is the Obseva SA dividend yield?
Obseva SA does not currently pay a dividend.
Does Obseva SA pay a dividend?
Obseva SA does not currently pay a dividend.
When does Obseva SA next pay dividends?
Obseva SA does not currently pay a dividend.
How do I buy Obseva SA shares?
To buy shares in Obseva SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Obseva SA?
As of the previous close price of CH₣0.00, shares in Obseva SA had a market capitalisation of CH₣0.14m.
Where are Obseva SA shares listed?
Here are the trading details for Obseva SA:
- Country of listing: Switzerland
- Exchange: SWX
- Ticker Symbol: OBSN
What kind of share is Obseva SA?
Based on an overall assessment of its quality, value and momentum Obseva SA is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Obseva SA share price forecast for 2024?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Obseva SA share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Obseva SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -97.71%.
As of the last closing price of CH₣0.00, shares in Obseva SA were trading -97.31% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Obseva SA PE Ratio?
The Obseva SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CH₣0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Obseva SA?
Obseva SA's management team is headed by:
- Frank Verwiel - NEC
- Brian O'Callaghan - CEO
- David Renas - CFO
- Fabien De Ladonchamps - CAD
- Jean-Pierre Gotteland - CSO
- Clive Bertram - OTH
- Elizabeth Garner - OTH
- Luigi Marro - OTH
- Ernest Loumaye - DRC
- Annette Clancy - IND
- Barbara Duncan - IND
- Edward Mathers - IND
- Jacky Vonderscher - IND